Anti-HBV Drugs: Progress, Unmet Needs, and New Hope

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2015 Sep 22

PMID 26389937

Citations 14

Authors

Lei Kang

Jiaqian Pan

Jiaofen Wu

Jiali Hu

Qian Sun

Jing Tang

Affiliations

Soon will be listed here.

Abstract

Approximately 240 million people worldwide are chronically infected with hepatitis B virus (HBV), which represents a significant challenge to public health. The current goal in treating chronic HBV infection is to block progression of HBV-related liver injury and inflammation to end-stage liver diseases, including cirrhosis and hepatocellular carcinoma, because we are unable to eliminate chronic HBV infection. Available therapies for chronic HBV infection mainly include nucleos/tide analogues (NAs), non-NAs, and immunomodulatory agents. However, none of them is able to clear chronic HBV infection. Thus, a new generation of anti-HBV drugs is urgently needed. Progress has been made in the development and testing of new therapeutics against chronic HBV infection. This review aims to summarize the state of the art in new HBV drug research and development and to forecast research and development trends and directions in the near future.

Citing Articles

A cell-penetrating bispecific antibody suppresses hepatitis B virus replication and secretion.

Xie C, Zhou B, Yao D, Wang X, Zhong L, Zhou L Virus Res. 2025; 353:199531.

PMID: 39863173 PMC: 11841211. DOI: 10.1016/j.virusres.2025.199531.

Improved pharmacokinetics of tenofovir ester prodrugs strengthened the inhibition of HBV replication and the rebalance of hepatocellular metabolism in preclinical models.

Hong X, Cai Z, Zhou F, Jin X, Wang G, Ouyang B Front Pharmacol. 2022; 13:932934.

PMID: 36105197 PMC: 9465247. DOI: 10.3389/fphar.2022.932934.

Effects of Resveratrol on Hepatitis B Virus Replication: In vitro and in vivo Experiments.

Pan P, Li J, Lin W, Long G Intervirology. 2022; 65(4):206-214.

PMID: 36088911 PMC: 9677841. DOI: 10.1159/000525807.

Clinical Features and Resistance to Entecavir Monotherapy of Patients with Hepatitis B.

Takayama H, Komura T, Kagaya T, Sugimoto S, Orita N, Asahina Y Can J Gastroenterol Hepatol. 2021; 2021:3259833.

PMID: 34422709 PMC: 8376438. DOI: 10.1155/2021/3259833.

Minicircle DNA vector expressing interferon-lambda-3 inhibits hepatitis B virus replication and expression in hepatocyte-derived cell line.

Guo X, Chen D, Cai Q, Huang Z, Xu W, Peng L BMC Mol Cell Biol. 2020; 21(1):6.

PMID: 32070272 PMC: 7027252. DOI: 10.1186/s12860-020-00250-9.

References

Yatsuji H, Suzuki F, Sezaki H, Akuta N, Suzuki Y, Kawamura Y . Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J Hepatol. 2008; 48(6):923-31. DOI: 10.1016/j.jhep.2008.02.019. View

Wolchok J, Kluger H, Callahan M, Postow M, Rizvi N, Lesokhin A . Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369(2):122-33. PMC: 5698004. DOI: 10.1056/NEJMoa1302369. View

Zhao Z, Jin Y, Gan Y, Zhu Y, Chen T, Wang J . Novel approach to identifying the hepatitis B virus pre-S deletions associated with hepatocellular carcinoma. World J Gastroenterol. 2014; 20(37):13573-81. PMC: 4188909. DOI: 10.3748/wjg.v20.i37.13573. View

Yao G, Zhu M, Cui Z, Wang B, Yao J, Zeng M . A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China. J Dig Dis. 2009; 10(2):131-7. DOI: 10.1111/j.1751-2980.2009.00375.x. View

Qi P, Chen Y, Wang H, Fang M, Ji Q, Zhao Y . -509C>T polymorphism in the TGF-beta1 gene promoter, impact on the hepatocellular carcinoma risk in Chinese patients with chronic hepatitis B virus infection. Cancer Immunol Immunother. 2009; 58(9):1433-40. PMC: 11030606. DOI: 10.1007/s00262-009-0660-4. View

Pang R, Tao J, Zhang S, Chen K, Zhao L, Yue X . Ethanol Extract from Ampelopsis sinica Root Exerts Anti-Hepatitis B Virus Activity via Inhibition of p53 Pathway In Vitro. Evid Based Complement Alternat Med. 2011; 2011:939205. PMC: 3130517. DOI: 10.1093/ecam/neq011. View

Janmanchi D, Tseng Y, Wang K, Huang R, Lin C, Yeh S . Synthesis and the biological evaluation of arylnaphthalene lignans as anti-hepatitis B virus agents. Bioorg Med Chem. 2010; 18(3):1213-26. DOI: 10.1016/j.bmc.2009.12.038. View

Bhattacharya D, Thio C . Review of hepatitis B therapeutics. Clin Infect Dis. 2010; 51(10):1201-8. PMC: 2977969. DOI: 10.1086/656624. View

Zhang Q, Han T, Nie C, Ha F, Liu L, Liu H . Tenofovir rescue regimen following prior suboptimal response to entecavir and adefovir combination therapy in chronic hepatitis B patients exposed to multiple treatment failures. J Med Virol. 2015; 87(6):1013-21. DOI: 10.1002/jmv.24153. View

10.

Wu Y, Zhao J, He M . Correlation between TGF-β1 gene 29 T > C single nucleotide polymorphism and clinicopathological characteristics of osteosarcoma. Tumour Biol. 2015; 36(7):5149-56. DOI: 10.1007/s13277-015-3168-x. View

11.

Stein L, Loomba R . Drug targets in hepatitis B virus infection. Infect Disord Drug Targets. 2009; 9(2):105-16. PMC: 6658185. DOI: 10.2174/187152609787847677. View

12.

Lu L, Zeng M, Mao Y, Li J, Wan M, Li C . Oxymatrine therapy for chronic hepatitis B: a randomized double-blind and placebo-controlled multi-center trial. World J Gastroenterol. 2003; 9(11):2480-3. PMC: 4656524. DOI: 10.3748/wjg.v9.i11.2480. View

13.

Ahmed M, Wang F, Levin A, Le C, Eltayebi Y, Houghton M . Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA. Drug Discov Today. 2015; 20(5):548-61. DOI: 10.1016/j.drudis.2015.01.008. View

14.

Chua P, Yung-Liang Wang R, Lin M, Masuda T, Suk F, Shih C . Reduced secretion of virions and hepatitis B virus (HBV) surface antigen of a naturally occurring HBV variant correlates with the accumulation of the small S envelope protein in the endoplasmic reticulum and Golgi apparatus. J Virol. 2005; 79(21):13483-96. PMC: 1262590. DOI: 10.1128/JVI.79.21.13483-13496.2005. View

15.

Xiang X, Xie Q . IL-35: a potential therapeutic target for controlling hepatitis B virus infection. J Dig Dis. 2014; 16(1):1-6. PMC: 7162105. DOI: 10.1111/1751-2980.12218. View

16.

Muckenfuss H, Hamdorf M, Held U, Perkovic M, Lower J, Cichutek K . APOBEC3 proteins inhibit human LINE-1 retrotransposition. J Biol Chem. 2006; 281(31):22161-22172. DOI: 10.1074/jbc.M601716200. View

17.

Tsukuda S, Watashi K, Iwamoto M, Suzuki R, Aizaki H, Okada M . Dysregulation of retinoic acid receptor diminishes hepatocyte permissiveness to hepatitis B virus infection through modulation of sodium taurocholate cotransporting polypeptide (NTCP) expression. J Biol Chem. 2015; 290(9):5673-84. PMC: 4342479. DOI: 10.1074/jbc.M114.602540. View

18.

Kamiya N, Kubota A, Iwase Y, Sekiya K, Ubasawa M, Yuasa S . Antiviral activities of MCC-478, a novel and specific inhibitor of hepatitis B virus. Antimicrob Agents Chemother. 2002; 46(9):2872-7. PMC: 127398. DOI: 10.1128/AAC.46.9.2872-2877.2002. View

19.

Carpenter M, Li M, Rathore A, Lackey L, Law E, Land A . Methylcytosine and normal cytosine deamination by the foreign DNA restriction enzyme APOBEC3A. J Biol Chem. 2012; 287(41):34801-8. PMC: 3464582. DOI: 10.1074/jbc.M112.385161. View

20.

Xu W, Zhao K, Miao X, Ni W, Cai X, Zhang R . Effect of oxymatrine on the replication cycle of hepatitis B virus in vitro. World J Gastroenterol. 2010; 16(16):2028-37. PMC: 2860082. DOI: 10.3748/wjg.v16.i16.2028. View